"The hardest years of my life," is how Cambridge scientist David Sabatini describes the time since his downfall from MIT.

Bipartisan legislation under review in Congress has the potential to significantly rejigger global drug development — and the biggest beneficiaries may not be American. The bill, titled the Biotech ...

Changes to the annual performance review process are the latest flashpoint in tensions between federal workers across the ...

The CEO of Compass Pathways said the company, whose psychedelic therapy is set for regulatory review this year, is prepared ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

White House planned shift of research funding from universities to industry risks creating a drought in basic research, ...

Working conditions are the larger problem. Burnout, chronic understaffing, and high turnover are among the most consistent ...

Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA ...

Was molecular biologist David Sabatini a manipulative mentor who coerced a younger colleague into sex? Or was he the victim ...

As I prepared for my appointment, the hospital asked me to sign its registration forms and to sign up for MyChart. In the ...

Ahead of "You Can See Everything" hitting theaters, let's rewind the last decade and review some of the most significant news ...

At the STAT Summit, the Department of Justice offered up a warning for health care executives: Don’t be another Theranos.